Ameriprise
ELDN icon

Ameriprise’s Eledon Pharmaceuticals ELDN Stock Holding History

Ameriprise’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-820
Closed -$731K – 3796
2016
Q2 		$731K Buy
820
+67
+9% +$73.9K ﹤0.01% 3012
2016
Q1 		$684K Sell
753
-1,007
-57% -$989K ﹤0.01% 3029
2015
Q4 		$2.48M Buy
1,760
+1,082
+160% +$1.89M ﹤0.01% 2474
2015
Q3 		$1.14M Sell
678
-168
-20% -$346K ﹤0.01% 2914
2015
Q2 		$1.82M Sell
846
-195
-19% -$377K ﹤0.01% 2819
2015
Q1 		$1.91M Sell
1,041
-63
-6% -$139K ﹤0.01% 2613
2014
Q4 		$2.64M Sell
1,104
-431
-28% -$1.02M ﹤0.01% 2426
2014
Q3 		$3.77M Buy
+1,535
New +$4.36M ﹤0.01% 2202

Other funds holding ELDN

BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EA
Emerald Acquisition Seattle, Washington $51.8B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameriprise's ELDN Position: Q3 2016 in Review

Ameriprise sold out of Eledon Pharmaceuticals (ELDN) in Q3 2016, closing a stake of 820 shares — an estimated $731K sold.

Ameriprise first reported a position in ELDN in Q3 2014 and held it in 8 quarters. The position peaked at $3.77M in Q3 2014. 44 funds tracked by Wall St. Rank hold ELDN as of Q3 2016.

  • Ameriprise reported no remaining Eledon Pharmaceuticals position as of Q3 2016 after selling out during the quarter.
  • Ameriprise sold 820 Eledon Pharmaceuticals shares in Q3 2016, an estimated $731K.
  • Ameriprise first reported a position in Eledon Pharmaceuticals in Q3 2014 and held it in 8 quarters.
  • Ameriprise's Eledon Pharmaceuticals position peaked at $3.77M in Q3 2014.
  • 44 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q3 2016.

Based on Ameriprise's 13F filing for Q3 2016, filed 8 Nov 2016.